MERUS B V

  • TickerMRUS
  • ISINNL0011606264
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

ValuEngine Rating and Forecast Report for MRUS

GlobalData Department

Merus NV (MRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Merus NV (Merus) is a clinical-stage immuno-oncology company that discovers and develops human bispecific antibody therapeutics for the treatment of cancer. The company’s pipeline antibody candidates are intended for the treatment of breast cancer, ovarian cancer, colorectal cancer, acute myeloid leukemia and other solid tumors. Merus develops its product candidates based on its proprietary technology platform biclonics, a bispecific, full length human IgG antibodies. The company has collaboration with Incyte Corporation, to develop preclinical bispecific antibody designed to bind to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch